Log in

NASDAQ:CRSPCrispr Therapeutics Stock Price, Forecast & News

$39.38
-0.13 (-0.33 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$39.10
Now: $39.38
$40.55
50-Day Range
$33.68
MA: $47.20
$58.12
52-Week Range
$32.30
Now: $39.38
$74.00
Volume531,702 shs
Average Volume970,823 shs
Market Capitalization$2.40 billion
P/E Ratio40.60
Dividend YieldN/A
Beta2.53
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; CTX120, a CAR-T cell product candidate for the treatment of multiple myeloma; CTX130 for the treatment of solid tumors and hematologic malignancies; programs to treat Hurler Syndrome and severe combined immunodeficiency disease, as well as glycogen storage disease Ia; and programs targeting diseases, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreements with Vertex Pharmaceuticals, Incorporated and Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use various therapeutics; and StrideBio LLC to develop adeno-associated viral capsids. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; ViaCyte, Inc. for designing, developing, and commercializing gene-edited allogeneic stem cell therapies for the treatment of diabetes; and ProBioGen AG to develop novel in vivo delivery modalities for CRISPR/Cas9. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Read More
Crispr Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRSP
CUSIPN/A
Phone41-41-561-3277

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$289.59 million
Cash Flow$1.29 per share
Book Value$17.02 per share

Profitability

Net Income$66.86 million

Miscellaneous

Employees188
Market Cap$2.40 billion
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive CRSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.


Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

How has Crispr Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Crispr Therapeutics' stock was trading at $43.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CRSP stock has decreased by 9.0% and is now trading at $39.38. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Crispr Therapeutics?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Crispr Therapeutics.

When is Crispr Therapeutics' next earnings date?

Crispr Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Crispr Therapeutics.

How were Crispr Therapeutics' earnings last quarter?

Crispr Therapeutics AG (NASDAQ:CRSP) posted its quarterly earnings data on Wednesday, February, 12th. The company reported $0.51 EPS for the quarter, beating the Zacks' consensus estimate of ($0.68) by $1.19. The business had revenue of $77 million for the quarter, compared to analysts' expectations of $39.08 million. Crispr Therapeutics had a net margin of 23.09% and a return on equity of 11.74%. The company's quarterly revenue was up 76900.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.92) EPS. View Crispr Therapeutics' earnings history.

What price target have analysts set for CRSP?

16 Wall Street analysts have issued 1-year price targets for Crispr Therapeutics' shares. Their forecasts range from $31.00 to $104.00. On average, they expect Crispr Therapeutics' share price to reach $74.42 in the next year. This suggests a possible upside of 89.0% from the stock's current price. View analysts' price targets for Crispr Therapeutics.

What are Wall Street analysts saying about Crispr Therapeutics stock?

Here are some recent quotes from research analysts about Crispr Therapeutics stock:
  • 1. According to Zacks Investment Research, "CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. " (3/24/2020)
  • 2. Needham & Company LLC analysts commented, "Crispr reported 1Q19 financial results yesterday and we spoke w/ mgmt for an update. The company announced last night that regulatory agencies in both the U.S. and Canada have cleared initiation of a Phase 1/2 trial of CTX-110, an allogeneic CAR-T cell therapy in development for CD-19 cancers. Mgmt reiterated guidance for trial initiation in 2Q19. 1/2 trials of CTX-001 continue to enroll pts, although infusion of first pt in latter trial is not expected until mid-2019. Mgmt still aspires to present data from the CTX-001 program at the ASH mtg in Dec 2019, depending on trial progress. Reiterate BUY. Progression of CRISPR-based allogeneic CAR-T program into the clinic later in 2Q19 represents important milestone for the company." (5/1/2019)

Has Crispr Therapeutics been receiving favorable news coverage?

News articles about CRSP stock have trended very negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Crispr Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutCrispr Therapeutics.

Are investors shorting Crispr Therapeutics?

Crispr Therapeutics saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 3,305,800 shares, an increase of 5.3% from the February 27th total of 3,140,000 shares. Based on an average daily volume of 906,900 shares, the days-to-cover ratio is presently 3.6 days. Currently, 12.5% of the company's shares are sold short. View Crispr Therapeutics' Current Options Chain.

Who are some of Crispr Therapeutics' key competitors?

What other stocks do shareholders of Crispr Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crispr Therapeutics investors own include Editas Medicine (EDIT), Micron Technology (MU), NVIDIA (NVDA), Intellia Therapeutics (NTLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Canopy Growth (CGC), Sangamo Therapeutics (SGMO), Intel (INTC) and Netflix (NFLX).

Who are Crispr Therapeutics' key executives?

Crispr Therapeutics' management team includes the following people:
  • Dr. Rodger Novak, Founder, Chairman & Pres (Age 52)
  • Dr. Samarth Kulkarni, CEO & Director (Age 40)
  • Mr. Michael John Tomsicek, Chief Financial Officer (Age 53)
  • Dr. Tony W. Ho, Head of R&D and Exec. VP
  • Dr. N. Anthony Coles Jr., Sr. Advisor (Age 59)

When did Crispr Therapeutics IPO?

(CRSP) raised $75 million in an IPO on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is Crispr Therapeutics' stock symbol?

Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

How do I buy shares of Crispr Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Crispr Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $39.38.

How big of a company is Crispr Therapeutics?

Crispr Therapeutics has a market capitalization of $2.40 billion and generates $289.59 million in revenue each year. The company earns $66.86 million in net income (profit) each year or $1.17 on an earnings per share basis. Crispr Therapeutics employs 188 workers across the globe. View additional information about Crispr Therapeutics.

What is Crispr Therapeutics' official website?

The official website for Crispr Therapeutics is http://www.crisprtx.com/.

How can I contact Crispr Therapeutics?

Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected]

This page was last updated on 4/4/2020 by MarketBeat.com Staff

Featured Article: What are economic reports?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel